AUB ScholarWorks

Hematopoietic stem cell allografting for chronic lymphocytic leukemia: A focus on reduced-intensity conditioning regimens

Show simple item record

dc.contributor.author Kharfan-Dabaja M.A.
dc.contributor.author Bazarbachi A.
dc.contributor.editor
dc.date Jan-2012
dc.date.accessioned 2017-10-05T15:43:29Z
dc.date.available 2017-10-05T15:43:29Z
dc.date.issued 2012
dc.identifier
dc.identifier.isbn
dc.identifier.issn 10732748
dc.identifier.uri http://hdl.handle.net/10938/18484
dc.description.abstract Background: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only known treatment modality that currently offers a potential cure to patients with chronic lymphocytic leukemia (CLL). A better understanding of the role of adoptive immunotherapy and its consequent bona fide graft-vs-leukemia (GVL) effect has resulted in a reduction of the ablative intensity and toxicity of preparative allo-HCT regimens. Methods: The authors review the published data of reduced-intensity conditioning (RIC) allo-HCT in patients with CLL. Results: RIC allo-HCT has reduced the transplant associated morbidity and mortality of the procedure and has consequently broadened applicability of allo-HCT to patients with CLL who are generally of more advanced age ( 60 years) and who often have associated comorbidities. Conclusions: Published literature supports the use of RIC allo-HCT for these patients once a suitable donor is identified, provided they fulfill acceptable consensus criteria for hematopoietic stem cell allografting. Several studies have shown that T-cell-replete RIC allo-HCT is also capable of overcoming the adverse effect of poor prognostic factors in CLL such as del(17p), unmutated IgVH, or ZAP-70 expression. Continued clinical trials to identify the optimal regimen for RIC allo-HCT for patients with CLL are warranted.
dc.format.extent
dc.format.extent Pages: (68-75)
dc.language English
dc.publisher TAMPA
dc.relation.ispartof Publication Name: Cancer Control; Publication Year: 2012; Volume: 19; no. 1; Pages: (68-75);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Hematopoietic stem cell allografting for chronic lymphocytic leukemia: A focus on reduced-intensity conditioning regimens
dc.type Review
dc.contributor.affiliation Kharfan-Dabaja, M.A., Department of Internal Medicine, Division of Hematology-Oncology, Naef K. Basile Cancer Institute, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, Division of Hematology-Oncology, Naef K. Basile Cancer Institute, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Kharfan-Dabaja, M. A.; Division of Hematology-Oncology and Bone Marrow Transplantation, Department of Internal Medicine, American University of Beirut, P.O. Box 11-0236, Beirut, Lebanon; email: MK143@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Naef K. Basile Cancer Institute (NKBCI);
dc.contributor.authorDepartment Naef K. Basile Cancer Institute (NKBCI)
dc.contributor.authorDivision
dc.contributor.authorEmail MK143@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Kharfan-Dabaja, MA
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Kharfan-Dabaja, MA (reprint author), Amer Univ Beirut, Dept Internal Med, Div Hematol Oncol and Bone Marrow Transplantat, POB 11-0236, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016-j.bbmt.2009.07.004; Brown JR, 2006, BIOL BLOOD MARROW TR, V12, P1056, DOI 10.1016-j.bbmt.2006.06.004; Caballero D, 2005, CLIN CANCER RES, V11, P7757, DOI 10.1158-1078-0432.CCR-05-0941; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056-NEJMoa023143; Delgado J, 2009, ANN ONCOL, V20, P2007, DOI 10.1093-annonc-mdp259; Delgado J, 2006, BLOOD, V107, P1724, DOI 10.1182-blood-2005-08-3372; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056-NEJM200012283432602; Doney KC, 2002, BONE MARROW TRANSPL, V29, P817, DOI 10.1038-sj-bmt-1703548; Dreger P, 2005, LEUKEMIA, V19, P1029, DOI 10.1038-sj.leu.2403745; Dreger P, 2010, BLOOD, V116, P2438, DOI 10.1182-blood-2010-03-275420; Dreger P, 2003, LEUKEMIA, V17, P841, DOI 10.1038-sj.leu.2402905; Dreger P, 2007, LEUKEMIA, V21, P12, DOI 10.1038-sj.leu.2404441; Elter T, 2005, J CLIN ONCOL, V23, P7024, DOI 10.1200-JCO.2005.01.9950; Fischer K, 2009, BLOOD, V114, P205; Goldin LR, 2009, HAEMATOL-HEMATOL J, V94, P647, DOI 10.3324-haematol.2008.003632; Gribben JG, 2005, BLOOD, V106, P4389, DOI 10.1182-blood-2005-05-1778; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182-blood.V99.3.1023; Kay NE, 2007, BLOOD, V109, P405, DOI 10.1182-blood-2006-07-033274; Kharfan-Dabaja MA, 2007, BRIT J HAEMATOL, V139, P234, DOI 10.1111-j.1365-2141.2007.06773.x; Khartan-Dabaja MA, 2008, CANCER, V113, P897, DOI 10.1002-cncr.23671; Kharfan-Dabaja MA, 2007, BIOL BLOOD MARROW TR, V13, P373, DOI 10.1016-j.bbmt.2007.01.075; Khouri IF, 2007, BRIT J HAEMATOL, V137, P355, DOI 10.1111-j.1365-2141.2007.06591.x; Khouri IF, 2001, BLOOD, V98, P3595, DOI 10.1182-blood.V98.13.3595; KOLB HJ, 1990, BLOOD, V76, P2462; Lamanna N, 2006, J CLIN ONCOL, V24, P1575, DOI 10.1200-JCO.2005.04.3836; Malhotra P, 2008, LEUKEMIA LYMPHOMA, V49, P1724, DOI 10.1080-10428190802263535; Michallet M, 1996, ANN INTERN MED, V124, P311; Michallet MM, 2003, BLOOD, V102, p474A; Nishida T, 2009, CLIN CANCER RES, V15, P4759, DOI 10.1158-1078-0432.CCR-09-0199; Pavletic ZS, 2005, J CONTRACEPT FERTIL, V23, P5788; Pavletic ZS, 2000, BONE MARROW TRANSPL, V25, P717, DOI 10.1038-sj.bmt.1702237; Peres E, 2009, BONE MARROW TRANSPL, V44, P579, DOI 10.1038-bmt.2009.61; Ritgen M, 2004, BLOOD, V104, P2600, DOI 10.1182-blood-2003-12-4321; Ritgen M, 2008, LEUKEMIA, V22, P1377, DOI 10.1038-leu.2008.96; Schetelig J, 2003, J CLIN ONCOL, V21, P2747, DOI 10.1200-JCO.2003.12.011; Schetelig J, 2008, J CLIN ONCOL, V26, P5094, DOI 10.1200-JCO.2008.16.2982; Slavin S, 1995, EXP HEMATOL, V23, P1553; Sorror ML, 2008, J CLIN ONCOL, V26, P4912, DOI 10.1200-JCO.2007.15.4757; Stem Cell Trialists' Collaborative Group, 2005, J CONTRACEPT FERTIL, V23, P5074; Tam CS, 2008, BLOOD, V112, P975, DOI 10.1182-blood-2008-02-140582; Toze CL, 2005, BONE MARROW TRANSPL, V36, P825, DOI 10.1038-sj.bmt.1705130; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200-JCO.2005.12.516
dc.description.citedCount 8
dc.description.citedTotWOSCount 12
dc.description.citedWOSCount 12
dc.format.extentCount 8
dc.identifier.articleNo
dc.identifier.coden CACOF
dc.identifier.pubmedID 22143063
dc.identifier.scopusID 83255164801
dc.identifier.url
dc.publisher.address 12902 MAGNOLIA DR, TAMPA, FL 33612 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Cancer Control
dc.relation.ispartOfIssue 1
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Cancer Control
dc.relation.ispartofPubTitleAbbr Cancer Control
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 19
dc.source.ID WOS:000307968300007
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS alemtuzumab, 216503-57-0
dc.subject.otherChemCAS busulfan, 55-98-1
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS fludarabine, 21679-14-1
dc.subject.otherChemCAS melphalan, 148-82-3
dc.subject.otherChemCAS protein kinase ZAP 70, 148047-34-1
dc.subject.otherChemCAS rituximab, 174722-31-7
dc.subject.otherIndex alemtuzumab
dc.subject.otherIndex busulfan
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex fludarabine
dc.subject.otherIndex immunoglobulin heavy chain
dc.subject.otherIndex melphalan
dc.subject.otherIndex protein kinase ZAP 70
dc.subject.otherIndex rituximab
dc.subject.otherIndex allogeneic hematopoietic stem cell transplantation
dc.subject.otherIndex cancer patient
dc.subject.otherIndex cancer risk
dc.subject.otherIndex chemoradiotherapy
dc.subject.otherIndex chronic lymphatic leukemia
dc.subject.otherIndex comorbidity
dc.subject.otherIndex disease association
dc.subject.otherIndex graft versus host reaction
dc.subject.otherIndex graft versus leukemia effect
dc.subject.otherIndex human
dc.subject.otherIndex morbidity
dc.subject.otherIndex mortality
dc.subject.otherIndex prognosis
dc.subject.otherIndex protein expression
dc.subject.otherIndex reduced intensity conditioning
dc.subject.otherIndex review
dc.subject.otherIndex treatment outcome
dc.subject.otherIndex Hematopoietic Stem Cell Transplantation
dc.subject.otherIndex Humans
dc.subject.otherIndex Leukemia, Lymphocytic, Chronic, B-Cell
dc.subject.otherIndex Prognosis
dc.subject.otherIndex Survival Analysis
dc.subject.otherIndex Transplantation Conditioning
dc.subject.otherIndex Treatment Outcome
dc.subject.otherKeywordPlus BONE-MARROW-TRANSPLANTATION
dc.subject.otherKeywordPlus TREATMENT-RELATED MORTALITY
dc.subject.otherKeywordPlus VARIABLE-REGION MUTATIONS
dc.subject.otherKeywordPlus VERSUS-HOST-DISEASE
dc.subject.otherKeywordPlus HEAVY-CHAIN GENE
dc.subject.otherKeywordPlus ALLOGENEIC TRANSPLANTATION
dc.subject.otherKeywordPlus POOR-PROGNOSIS
dc.subject.otherKeywordPlus CLL3X TRIAL
dc.subject.otherKeywordPlus CYCLOPHOSPHAMIDE
dc.subject.otherKeywordPlus RITUXIMAB
dc.subject.otherWOS Oncology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account